Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders

J M Brickman, M Clements, R Tyrell, D McNay, K Woods, J Warner, A Stewart, R S Beddington, M Dattani

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

The homeobox gene Hesx1/HESX1 has been implicated in the establishment of anterior pattern in the central nervous system (CNS) in a number of vertebrate species. Its role in pituitary development has been documented through loss-of-function studies in the mouse. A homozygous missense point mutation resulting in a single amino acid substitution, Arg160Cys (R160C), is associated with a heritable form of the human condition of septo-optic dysplasia (SOD). We have examined the phenotype of affected members in this pedigree in more detail and demonstrate for the first time a genetic basis for midline defects associated with an undescended or ectopic posterior pituitary. A similar structural pituitary abnormality was observed in a second patient heterozygous for another mutation in HESX1, Ser170Leu (S170L). Association of S170L with a pituitary phenotype may be a direct consequence of the HESX1 mutation since S170L is also associated with a dominant familial form of pituitary disease. However, a third mutation in HESX1, Asn125Ser (N125S), occurs at a high frequency in the Afro-Caribbean population and may therefore reflect a population-specific polymorphism. To investigate the molecular basis for these clinical phenotypes, we have examined the impact of these mutations on the regulatory functions of HESX1. We show that Hesx1 is a promoter-specific transcriptional repressor with a minimal 36 amino acid repression domain which can mediate promoter-specific repression by suppressing the activity of homeodomain-containing activator proteins. Mutations in HESX1 associated with pituitary disease appear to modulate the DNA-binding affinity of HESX1 rather than its transcriptional activity. Wild-type HESX1 binds a dimeric homeodomain site with high affinity (K(d) 31 nM) whilst HESX1(S170L) binds with a 5-fold lower activity (K(d) 150 nM) and HESX1(R160C) does not bind at all. Although HESX1(R160C) has only been shown to be associated with the SOD phenotype in children homozygous for the mutation, HESX1(R160C) can inhibit DNA binding by wild-type HESX1 both in vitro and in vivo in cell culture. This dominant negative activity of HESX1(R160C) is mediated by the Hesx1 repression domain, supporting the idea that the repression domain is implicated in interactions between homeodomain proteins. Our data suggest a possible molecular paradigm for the dominant inheritance observed in some pituitary disorders.
Original languageEnglish
Pages (from-to)5189-99
Number of pages11
JournalDevelopment
Volume128
Issue number24
Publication statusPublished - 2001

Fingerprint

Pituitary Diseases
Mutation
Septo-Optic Dysplasia
Phenotype
Homeodomain Proteins
Homeobox Genes
DNA
Missense Mutation
Amino Acid Substitution
Pedigree
Point Mutation
Population
Vertebrates
Central Nervous System
Cell Culture Techniques
Amino Acids

Keywords

  • Animals
  • Basic Helix-Loop-Helix Transcription Factors
  • Child
  • Genes, Homeobox
  • Homeodomain Proteins
  • Humans
  • Mice
  • Mutation
  • Pituitary Diseases
  • Protein Binding
  • Repressor Proteins
  • Septo-Optic Dysplasia

Cite this

Brickman, J. M., Clements, M., Tyrell, R., McNay, D., Woods, K., Warner, J., ... Dattani, M. (2001). Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Development, 128(24), 5189-99.

Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. / Brickman, J M; Clements, M; Tyrell, R; McNay, D; Woods, K; Warner, J; Stewart, A; Beddington, R S; Dattani, M.

In: Development, Vol. 128, No. 24, 2001, p. 5189-99.

Research output: Contribution to journalArticle

Brickman, JM, Clements, M, Tyrell, R, McNay, D, Woods, K, Warner, J, Stewart, A, Beddington, RS & Dattani, M 2001, 'Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders', Development, vol. 128, no. 24, pp. 5189-99.
Brickman JM, Clements M, Tyrell R, McNay D, Woods K, Warner J et al. Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Development. 2001;128(24):5189-99.
Brickman, J M ; Clements, M ; Tyrell, R ; McNay, D ; Woods, K ; Warner, J ; Stewart, A ; Beddington, R S ; Dattani, M. / Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. In: Development. 2001 ; Vol. 128, No. 24. pp. 5189-99.
@article{3dd598c307864d58a474866db463bbbb,
title = "Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders",
abstract = "The homeobox gene Hesx1/HESX1 has been implicated in the establishment of anterior pattern in the central nervous system (CNS) in a number of vertebrate species. Its role in pituitary development has been documented through loss-of-function studies in the mouse. A homozygous missense point mutation resulting in a single amino acid substitution, Arg160Cys (R160C), is associated with a heritable form of the human condition of septo-optic dysplasia (SOD). We have examined the phenotype of affected members in this pedigree in more detail and demonstrate for the first time a genetic basis for midline defects associated with an undescended or ectopic posterior pituitary. A similar structural pituitary abnormality was observed in a second patient heterozygous for another mutation in HESX1, Ser170Leu (S170L). Association of S170L with a pituitary phenotype may be a direct consequence of the HESX1 mutation since S170L is also associated with a dominant familial form of pituitary disease. However, a third mutation in HESX1, Asn125Ser (N125S), occurs at a high frequency in the Afro-Caribbean population and may therefore reflect a population-specific polymorphism. To investigate the molecular basis for these clinical phenotypes, we have examined the impact of these mutations on the regulatory functions of HESX1. We show that Hesx1 is a promoter-specific transcriptional repressor with a minimal 36 amino acid repression domain which can mediate promoter-specific repression by suppressing the activity of homeodomain-containing activator proteins. Mutations in HESX1 associated with pituitary disease appear to modulate the DNA-binding affinity of HESX1 rather than its transcriptional activity. Wild-type HESX1 binds a dimeric homeodomain site with high affinity (K(d) 31 nM) whilst HESX1(S170L) binds with a 5-fold lower activity (K(d) 150 nM) and HESX1(R160C) does not bind at all. Although HESX1(R160C) has only been shown to be associated with the SOD phenotype in children homozygous for the mutation, HESX1(R160C) can inhibit DNA binding by wild-type HESX1 both in vitro and in vivo in cell culture. This dominant negative activity of HESX1(R160C) is mediated by the Hesx1 repression domain, supporting the idea that the repression domain is implicated in interactions between homeodomain proteins. Our data suggest a possible molecular paradigm for the dominant inheritance observed in some pituitary disorders.",
keywords = "Animals, Basic Helix-Loop-Helix Transcription Factors, Child, Genes, Homeobox, Homeodomain Proteins, Humans, Mice, Mutation, Pituitary Diseases, Protein Binding, Repressor Proteins, Septo-Optic Dysplasia",
author = "Brickman, {J M} and M Clements and R Tyrell and D McNay and K Woods and J Warner and A Stewart and Beddington, {R S} and M Dattani",
year = "2001",
language = "English",
volume = "128",
pages = "5189--99",
journal = "Development",
issn = "0950-1991",
publisher = "Company of Biologists Ltd",
number = "24",

}

TY - JOUR

T1 - Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders

AU - Brickman, J M

AU - Clements, M

AU - Tyrell, R

AU - McNay, D

AU - Woods, K

AU - Warner, J

AU - Stewart, A

AU - Beddington, R S

AU - Dattani, M

PY - 2001

Y1 - 2001

N2 - The homeobox gene Hesx1/HESX1 has been implicated in the establishment of anterior pattern in the central nervous system (CNS) in a number of vertebrate species. Its role in pituitary development has been documented through loss-of-function studies in the mouse. A homozygous missense point mutation resulting in a single amino acid substitution, Arg160Cys (R160C), is associated with a heritable form of the human condition of septo-optic dysplasia (SOD). We have examined the phenotype of affected members in this pedigree in more detail and demonstrate for the first time a genetic basis for midline defects associated with an undescended or ectopic posterior pituitary. A similar structural pituitary abnormality was observed in a second patient heterozygous for another mutation in HESX1, Ser170Leu (S170L). Association of S170L with a pituitary phenotype may be a direct consequence of the HESX1 mutation since S170L is also associated with a dominant familial form of pituitary disease. However, a third mutation in HESX1, Asn125Ser (N125S), occurs at a high frequency in the Afro-Caribbean population and may therefore reflect a population-specific polymorphism. To investigate the molecular basis for these clinical phenotypes, we have examined the impact of these mutations on the regulatory functions of HESX1. We show that Hesx1 is a promoter-specific transcriptional repressor with a minimal 36 amino acid repression domain which can mediate promoter-specific repression by suppressing the activity of homeodomain-containing activator proteins. Mutations in HESX1 associated with pituitary disease appear to modulate the DNA-binding affinity of HESX1 rather than its transcriptional activity. Wild-type HESX1 binds a dimeric homeodomain site with high affinity (K(d) 31 nM) whilst HESX1(S170L) binds with a 5-fold lower activity (K(d) 150 nM) and HESX1(R160C) does not bind at all. Although HESX1(R160C) has only been shown to be associated with the SOD phenotype in children homozygous for the mutation, HESX1(R160C) can inhibit DNA binding by wild-type HESX1 both in vitro and in vivo in cell culture. This dominant negative activity of HESX1(R160C) is mediated by the Hesx1 repression domain, supporting the idea that the repression domain is implicated in interactions between homeodomain proteins. Our data suggest a possible molecular paradigm for the dominant inheritance observed in some pituitary disorders.

AB - The homeobox gene Hesx1/HESX1 has been implicated in the establishment of anterior pattern in the central nervous system (CNS) in a number of vertebrate species. Its role in pituitary development has been documented through loss-of-function studies in the mouse. A homozygous missense point mutation resulting in a single amino acid substitution, Arg160Cys (R160C), is associated with a heritable form of the human condition of septo-optic dysplasia (SOD). We have examined the phenotype of affected members in this pedigree in more detail and demonstrate for the first time a genetic basis for midline defects associated with an undescended or ectopic posterior pituitary. A similar structural pituitary abnormality was observed in a second patient heterozygous for another mutation in HESX1, Ser170Leu (S170L). Association of S170L with a pituitary phenotype may be a direct consequence of the HESX1 mutation since S170L is also associated with a dominant familial form of pituitary disease. However, a third mutation in HESX1, Asn125Ser (N125S), occurs at a high frequency in the Afro-Caribbean population and may therefore reflect a population-specific polymorphism. To investigate the molecular basis for these clinical phenotypes, we have examined the impact of these mutations on the regulatory functions of HESX1. We show that Hesx1 is a promoter-specific transcriptional repressor with a minimal 36 amino acid repression domain which can mediate promoter-specific repression by suppressing the activity of homeodomain-containing activator proteins. Mutations in HESX1 associated with pituitary disease appear to modulate the DNA-binding affinity of HESX1 rather than its transcriptional activity. Wild-type HESX1 binds a dimeric homeodomain site with high affinity (K(d) 31 nM) whilst HESX1(S170L) binds with a 5-fold lower activity (K(d) 150 nM) and HESX1(R160C) does not bind at all. Although HESX1(R160C) has only been shown to be associated with the SOD phenotype in children homozygous for the mutation, HESX1(R160C) can inhibit DNA binding by wild-type HESX1 both in vitro and in vivo in cell culture. This dominant negative activity of HESX1(R160C) is mediated by the Hesx1 repression domain, supporting the idea that the repression domain is implicated in interactions between homeodomain proteins. Our data suggest a possible molecular paradigm for the dominant inheritance observed in some pituitary disorders.

KW - Animals

KW - Basic Helix-Loop-Helix Transcription Factors

KW - Child

KW - Genes, Homeobox

KW - Homeodomain Proteins

KW - Humans

KW - Mice

KW - Mutation

KW - Pituitary Diseases

KW - Protein Binding

KW - Repressor Proteins

KW - Septo-Optic Dysplasia

M3 - Article

C2 - 11748154

VL - 128

SP - 5189

EP - 5199

JO - Development

JF - Development

SN - 0950-1991

IS - 24

ER -